Register Login

BIODEXA PHARMACEUTICALS PLC (BDRX)

SymbolBDRX
NameBIODEXA PHARMACEUTICALS PLC
SectorHEALTH CARE
RegionEurope
IndustryBiotechnology: Pharmaceutical Preparations
Address1 CASPIAN POINT,CASPIAN WAY, CARDIFF, CF10 4DQ, United Kingdom
Telephone+44 2920480180
Fax—
Email—
Websitehttps://www.biodexapharma.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001643918
Description

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Companys lead development programs include eRapa, in Phase 3 development for Familial Adenomatous Polyposis; tolimidone, in Phase 2 development for the treatment of type 1 diabetes; and MTX110, in Phase 1 development in aggressive rare/orphan brain cancer indications.

Additional info from NASDAQ:
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Companys lead development programs include eRapa, in Phase 3 development for Familial Adenomatous Polyposis; tolimidone, in Phase 2 development for the treatment of type 1 diabetes; and MTX110, in Phase 1 development in aggressive rare/orphan brain cancer indications.

2026-07-15 17:12

New Form F-1 - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-07-15 <b>AccNo:</b> 0001214659-26-008591 <b>Size:</b> 1 MB

Read more
2026-07-01 07:15

New Form 424B5 - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-07-01 <b>AccNo:</b> 0001214659-26-007998 <b>Size:</b> 202 KB

Read more
2026-06-30 20:30

Result of Annual General Meeting

Read more
2026-06-29 12:30

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress

Read more
2026-06-17 20:30

Postponement and Re-scheduling of Annual General Meeting

Read more
2026-05-15 12:08

New Form SCHEDULE 13G/A - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001172661-26-002131 <b>Size:</b> 10 KB

Read more
2026-05-14 12:30

Biodexa issues letter to Shareholders

Read more
2026-04-02 17:29

New Form 424B3 - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001214659-26-004256 <b>Size:</b> 550 KB

Read more
2026-04-02 17:29

New Form 424B3 - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001214659-26-004254 <b>Size:</b> 549 KB

Read more
2026-04-02 17:29

New Form 424B3 - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001214659-26-004255 <b>Size:</b> 589 KB

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07689942 Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis — Familial Adenomatous Polyposis (FAP) Available — — ClinicalTrials.gov
NCT06950385 Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis Phase3 Familial Adenomatous Polyposis (FAP) Recruiting 2025-07-18 2031-01-01 ClinicalTrials.gov
NCT05324501 A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Gliobla… Phase1 Recurrent Glioblastoma Terminated 2022-10-19 2024-09-10 ClinicalTrials.gov
NCT04230499 Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patient… Phase2 Familial Adenomatous Polyposis Active_Not_Recruiting 2021-01-18 2025-03-01 ClinicalTrials.gov
Total clinical trials: 4
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
eRapa (encapsulated rapamycin) Other Preclinical Familial Adenomatous Polyposis (FAP) AVAILABLE NCT07689942
Placebo Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
eRapa (encapsulated rapamycin) Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
Placebo Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
eRapa (encapsulated rapamycin) Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
Placebo Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
eRapa (encapsulated rapamycin) Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
Placebo Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
eRapa (encapsulated rapamycin) Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
Placebo Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
eRapa (encapsulated rapamycin) Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
Placebo Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
eRapa (encapsulated rapamycin) Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
Encapsulated Rapamycin (eRapa) Other Phase PHASE2 Familial Adenomatous Polyposis ACTIVE_NOT_RECRUITING NCT04230499
Programmable pump and catheter system Other Phase PHASE1 Recurrent Glioblastoma TERMINATED NCT05324501
MTX110 Other Phase PHASE1 Recurrent Glioblastoma TERMINATED NCT05324501
Placebo Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
eRapa (encapsulated rapamycin) Other Phase PHASE3 Familial Adenomatous Polyposis (FAP) RECRUITING NCT06950385
Total products: 18